EpicentRx presents new clinical data at CTOS 2026

On November 12, 2026 EpicentRx reported its CEO Dr. Tony Reid will be at The Connective Tissue Oncology Society 2026 Annual Meeting taking place November 18–21, 2026, in Seoul, South Korea. New clinical data from the Phase 1/2 BETAPRIME trial will be presented in the abstract entitled: ADAPT-001 with a checkpoint inhibitor in angiosarcoma refractory to checkpoint inhibition: activity and durability of response.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, EpicentRx, NOV 12, 2026, View Source [SID1234674672])

TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

On November 12, 2026 TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, reported financial results for the three months ended September 30, 2026, and provided a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This quarter marked an important step in accelerating TScan’s solid tumor program. We are concentrating all our efforts on our in vivo-engineered TCR-T cell approach for solid tumor indications, where we see an opportunity to bring an exciting new treatment modality to patients in desperate need of better treatment options. Our team is working to advance our two lead candidates through preclinical development and complete the studies required to support clinical entry, with the goal of dosing our first patient by the fourth quarter of next year," said Gavin MacBeath, Ph.D., Chief Executive Officer. "At the same time, we are actively pursuing strategic partnerships to advance our heme malignancies and autoimmunity programs. We are excited about the progress we have made this year on our in vivo TCR-T candidates and look forward to sharing more of our preclinical data and FDA feedback in early 2027."

Recent Corporate Highlights

•
In September, the Company announced a strategic reorganization to prioritize its in vivo solid tumor program. TScan’s first two therapeutic candidates, one targeting PRAME and the other targeting MAGE-A4, were advanced to IND-enabling studies.
•
The Company also provided updated data in September from Cohort C of its Phase 1 ALLOHA study of TSC-101 in heme malignancies. At the time of the update, all 14 patients in Cohort C of the study showed complete donor chimerism at their last assessment, including the two patients who had previously relapsed. The Company paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital needed to complete the trial and is actively seeking strategic partnerships. TScan remains committed to tracking the patients enrolled in Cohort C of the Phase 1 study, as well as the 7 patients who were enrolled on the treatment arm of the Phase 3 ALLOHA-2 study and the five patients enrolled on the control arm of ALLOHA-2.

Pipeline Progress and Upcoming Anticipated Milestones

Solid Tumor Program: The Company’s strategy is to treat patients with in vivo-engineered TCR-T therapy candidates, initially as singleplexed therapy and ultimately as multiplexed therapy. The Company currently has two candidates in IND-enabling studies: one targeting PRAME and the other targeting MAGE-A4.

Anticipated Milestones

•
Disclose preclinical data and FDA feedback from pre-IND meetings on TSC-303-A02 (PRAME) and TSC-302-A02 (MAGE-A4) in Q1 2027.
•
File the first IND for in vivo-engineered TCR-T for solid tumors in Q3 2027, with first patient dosed in Q4 2027.
•
Report initial Phase 1 data on in vivo-engineered TCR-T in H1 2028.

Heme Malignancies Program: TScan’s TCR-T therapy candidate, TSC-101, is designed to treat residual disease and prevent relapse in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). TScan is currently seeking strategic partners for this program.

Anticipated Milestones

•
Share updated data on patients treated in Cohort C of the Phase 1 ALLOHA study at the upcoming 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition in Q4 2026.
Title: Phase 1 (ALLOHA) trial cohort C: TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved outcomes in patients with AML, ALL, or MDS post-allogeneic RIC HCT

Publication Number: 4178

Presentation Date and Time: December 13, 2026, 6:00 – 8:00 pm E.T.

•
Share updated data, including >1 year of follow-up time, on Cohort C patients of the ALLOHA study, and new data, including >6 months of follow-up time, on patients enrolled in the ALLOHA-2 study, in the first half of 2027.

Autoimmunity Program: The Company has discovered novel targets for ankylosing spondylitis and other HLA-B*27-associated autoimmune disorders and is currently seeking strategic partners for this program.

Third Quarter 2026 Financial Results

Revenue: Revenue for the third quarter of 2026 was $0.6 million, compared to $2.5 million for the third quarter of 2025. The decrease was primarily due to timing of research activities pursuant to the Company’s collaboration agreement with Amgen, which was terminated in August 2026.

R&D Expenses: Research and development (R&D) expenses for the third quarter of 2026 were $25.3 million, compared to $31.7 million for the third quarter of 2025. The decrease of $6.4 million was primarily driven by a decrease in laboratory supplies, research materials, and studies due to the timing in the purchase of supplies and consumables, and decrease spend on contracted services, as well as savings in connection with the 2025 workforce reduction. R&D expenses included non-cash stock compensation expense of $1.0 million and $1.7 million for the third quarter of 2026 and 2025, respectively.

G&A Expenses: General and administrative (G&A) expenses for the third quarter of 2026 were $8.3 million, compared to $7.9 million for the third quarter of 2025. The increase of $0.5 million was primarily due to costs incurred in connection with the 2026 reorganization. G&A expenses included non-cash stock compensation expense of $1.1 million and $1.3 million for the third quarter of 2026 and 2025, respectively.

Net Loss: Net loss was $33.1 million for the third quarter of 2026, compared to $35.7 million for the third quarter of 2025, and included net interest expense of $0.1 million and net interest income of $1.3 million, respectively.

Cash Position: Cash and cash equivalents as of September 30, 2026, were $73.0 million, excluding $5.0 million of restricted cash. The Company believes that its existing cash resources will be sufficient to fund its current operating plan into the fourth quarter of 2027. The Company did not achieve certain non-covenant related milestones by June 30, 2026 as provided under its existing debt agreement. The updated cash runway therefore reflects commencement of the two-year term loan amortization beginning in the fourth quarter of 2026.

Share Count: As of September 30, 2026, the Company had 67,779,255 issued and outstanding shares of common stock, consisting of 63,502,667 shares of voting common stock and 4,276,588 shares of non-voting common stock, as well as 62,246,707 outstanding pre-funded warrants to purchase shares of voting common stock at an exercise price of $0.0001 per share. Pro forma outstanding shares, inclusive of both common stock and pre-funded warrants, were 130,025,962 as of September 30, 2026.

(Press release, TScan Therapeutics, NOV 12, 2026, View Source [SID1234674688])

Enhertu® Supplemental New Drug Application Submitted in Japan for Patients with HER2 Expressing Advanced or Recurrent Uterine Carcinosarcoma

On November 15, 2026 Daiichi Sankyo (TSE: 4568) reported it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Enhertu (trastuzumab deruxtecan) for the treatment of patients with HER2 expressing (immunohistochemistry [IHC] 3+, IHC 2+ or IHC 1+) advanced or recurrent uterine carcinosarcoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being developed and commercialized by Daiichi Sankyo in Japan.

The sNDA is based on data from the STATICE phase 2 trial, an investigator-initiated trial conducted in Japan, which was published in the Journal of Clinical Oncology. In the trial, Enhertu (5.4 mg/kg) demonstrated durable responses across levels of HER2 expression in patients with advanced or recurrent uterine carcinosarcoma previously treated with chemotherapy (including adjuvant chemotherapy). STATICE is the first prospective trial to show clinical activity with a HER2 directed medicine in this rare form of cancer.

"Patients with HER2 expressing advanced uterine carcinosarcoma in Japan face a poor prognosis, with treatment relying on chemotherapy rather than options directed at a specific molecular target," said Yuki Abe, PhD, Senior Executive Officer, Head of R&D Division in Japan and Head of Research, Daiichi Sankyo. "The durable activity demonstrated in the STATICE trial underscores the benefit of targeting HER2 with Enhertu in this difficult-to-treat cancer. If approved, Enhertu could provide an important targeted treatment option for patients with uterine carcinosarcoma in Japan."

Enhertu currently is approved in more than 50 countries/regions worldwide to treat patients with HER2 positive (IHC 3+) solid tumors who have received prior treatment and/or who have no satisfactory treatment options. In Japan, Enhertu can be considered as a treatment option for patients with HER2 positive (HER2 [ERBB2] gene amplification or IHC 3+) uterine carcinosarcoma when standard treatment is not appropriate.

Enhertu also is under review in Japan as an adjuvant treatment for patients with HER2 positive (IHC 3+ or in-situ hybridization (ISH)+) breast cancer with residual invasive disease after neoadjuvant therapy based on data from DESTINY-Breast05.

About STATICE

STATICE is a multicenter, open-label, single-arm investigator-initiated phase 2 trial evaluating the efficacy and safety of Enhertu (6.4 or 5.4 mg/kg) in patients in Japan with HER2 expressing (HER2 IHC 3+, IHC 2+ or IHC 1+) advanced or recurrent uterine carcinosarcoma who have received prior chemotherapy (including adjuvant chemotherapy). At trial initiation, Enhertu 6.4 mg/kg was administered; however, based on an assessment of risk/benefit, the dosing was modified mid-trial to 5.4 mg/kg and was determined to be the preferred dose for this patient population.

The primary endpoint of STATICE is objective response rate (ORR) as assessed by central review in patients with HER2 expressing tumors with IHC ≥ 2+. Secondary endpoints include investigator-assessed ORR in patients with HER2 expressing tumors with IHC ≥ 2+, ORR by central review and investigator assessment in patients with HER2 IHC 1+ tumors, progression-free survival (PFS), overall survival (OS) and safety. Results from STATICE were published in the Journal of Clinical Oncology.

STATICE enrolled 34 patients across seven sites in Japan. For more information about the trial, visit Japan’s University Hospital Medical Information Network.

About Uterine Carcinosarcoma

Uterine carcinosarcoma is a rare, highly aggressive form of endometrial cancer that accounts for fewer than 5% of endometrial cancer cases in Japan.1,2,3 Despite its rarity, uterine carcinosarcoma is estimated to account for approximately 15% of endometrial cancer-related deaths.3 Prognosis remains poor, with lower overall survival for uterine carcinosarcoma compared to other types of endometrial cancer and particularly poor outcomes reported following later lines of treatment in recurrent or metastatic uterine carcinosarcoma.

HER2 is a tyrosine kinase receptor protein involved in cell growth and differentiation and expressed on the surface of multiple tumor types.6 HER2 expression (IHC 3+, IHC 2+, or IHC 1+) was observed in 72.3% of patients with uterine carcinosarcoma, supporting HER2 as a potential therapeutic target.7 Pre-clinical trials evaluating HER2 targeted therapies showed promising antitumor effects, supporting the potential of HER2 as a therapeutic target in uterine carcinosarcoma.

In Japan, paclitaxel plus carboplatin chemotherapy is commonly used as systemic treatment for unresectable, advanced uterine carcinosarcoma, including recurrent disease.11,12,13 However, median disease-free survival with this regimen is less than two years and disease recurrence occurs in 57% of patients with uterine carcinosarcoma.

About Enhertu

Enhertu (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki in the U.S. only) is a HER2 directed ADC. Designed using the proprietary DXd ADC Technology of Daiichi Sankyo, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

Enhertu (5.4 mg/kg) followed by THP is approved in more than five countries/regions worldwide as a neoadjuvant treatment for adult patients with HER2 positive (IHC 3+ or ISH+) stage 2 or stage 3 breast cancer based on the results from the DESTINY-Breast11 trial.

Enhertu (5.4 mg/kg) is approved in more than 35 countries/regions worldwide for the adjuvant treatment of adult patients with HER2 positive breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment based on the DESTINY-Breast05 trial.

Enhertu (5.4 mg/kg) in combination with pertuzumab is approved in more than 40 countries/regions worldwide as a first-line treatment for adult patients with unresectable or metastatic HER2 positive (IHC 3+ or ISH+) breast cancer, as determined by a locally or regionally approved test, based on the results from the DESTINY-Breast09 trial.

Enhertu (5.4 mg/kg) is approved in more than 100 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2 positive (IHC 3+ or ISH+) breast cancer who have received a prior antiHER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have 3 developed disease recurrence during or within six months of completing therapy based on the results from the DESTINY-Breast03 trial

Enhertu (5.4 mg/kg) is approved in more than 75 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer, as determined by a locally or regionally approved test, that have progressed on one or more endocrine therapies in the metastatic setting based on the results from the DESTINY-Breast06 trial.

Enhertu (5.4 mg/kg) is approved in more than 100 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results from the DESTINY-Breast04 trial.

Enhertu (5.4 mg/kg) is approved in more than 80 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, as detected by a locally or regionally approved test, and who have received a prior systemic therapy based on the results from the DESTINY-Lung02 and/or DESTINY-Lung05 trials. Continued approval in China and the U.S. for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Enhertu (6.4 mg/kg) is approved in more than 90 countries/regions worldwide for the treatment of adult patients with locally advanced or metastatic HER2 positive (IHC 3+ or IHC 2+/ISH+) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01, DESTINY-Gastric02 and/or DESTINY-Gastric04 trials.

Enhertu (5.4 mg/kg) is approved in more than 50 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2 positive (IHC 3+) solid tumors who have received prior treatment and/or have no satisfactory alternative treatment options based on efficacy results from the DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02, DESTINY-PanTumor03 and/or HERALD trials. Continued approval in China and the U.S. for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

(Press release, Daiichi Sankyo, NOV 12, 2026, View Source [SID1234674707])

Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials

On November 12, 2026 Biolojic Design, a biotechnology company that uses AI to create antibodies that act as programmable, intelligent therapeutic candidates, reported that the U.S. FDA has cleared the Investigational New Drug (IND) application for BD200, a multibody drug conjugate that targets both Trop2 and Nectin-4. The IND clearance enables initiation of Biolojic’s planned global Phase 1 clinical study in the United States focusing on patients with select solid tumors known to express Trop2 and Nectin-4.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The FDA’s clearance of our IND for BD200 is a significant step toward advancing the first multibody into clinical testing," said Yanay Ofran, Ph.D., CEO and founder of Biolojic Design. "In addition to marking an important milestone in the evolution of multi-specific antibodies, it is also an important achievement in the application of AI to drug design by showing that AI can support the creation of antibodies with unique properties and potentially transformative capabilities. We look forward to starting our Phase 1 study in the coming weeks."

"As we look to improve cancer treatment, the heterogeneity of tumor antigen expression and the development of resistance are significant challenges," said Roger Waltzman, M.D., Chief Medical Officer of Biolojic Design "As a multibody, BD200 has been designed to help overcome these hurdles with a flexible binding profile and a unique linker-payload profile that enables it to adapt to an individual patient’s tumor expression, potentially improving efficacy and safety."

Multibodies are standard-format, multi-specific antibodies in which each arm can alternatively bind to one or both of two targets. Targeting the validated oncology antigens Nectin-4 and Trop2, both of which may be expressed by a cancer cell, each arm of BD200 can individually bind to either antigen, with the goal of overcoming target expression heterogeneity and enabling BD200 to address a patient’s specific tumor antigen expression profile.

The BD200 Phase 1 Clinical Study

The Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of BD200 in patients with tumors known to express these antigens. The study will be conducted in the U.S and globally. Once optimal biologic doses have been selected, the study will focus on one or more appropriate tumor types as well as potential monotherapy and combination therapy development pathways.

About BD200

BD200 is a multibody drug conjugate carrying a potent topoisomerase inhibitor payload that targets Trop2 and Nectin-4, two antigens that are expressed in a variety of solid tumors. As a multibody, BD200 can bind to Nectin-4 with both arms, Trop2 with both arms, or Trop2 with one arm and Nectin-4 with a second arm. In preclinical studies, BD200 was able to bind to both of these targets and adapt its specificity to the heterogeneous antigen expression on tumor cells, increasing efficacy and overcoming resistance when compared to standard monospecific antibody drug conjugates (ADCs) or a template bispecific ADC.

(Press release, Biolojic Design, NOV 12, 2026, View Source [SID1234674724])

Erasca Reports Third Quarter 2026 Business Updates and Financial Results

On November 12, 2026 Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported business updates and announced financial results for the fiscal quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The emerging clinical profile of ERAS-0015 continues to support its potential as a foundational therapy across RAS-mutant cancers, both as a monotherapy and backbone for combination regimens," said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. "We are rapidly advancing toward three potentially registration-enabling trials in pancreatic and lung cancers. We are pleased that ERAS-0015 received Fast Track Designation for metastatic pancreatic cancer, which offers an opportunity for closer engagement with the FDA as we progress the program. With a strengthened balance sheet and experienced R&D leadership, we believe that we are positioned to execute our near-term milestones and advance programs addressing high unmet needs for patients with RAS-mutant cancers."

Research and Development (R&D) Highlights

•
FDA Fast Track Designation for ERAS-0015: In August 2026, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma. The designation is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical needs and provides opportunities for more frequent FDA interactions as Erasca advances its planned Phase 3 trial in pancreatic cancer.
•
Presentations at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium: In September 2026, Erasca announced two presentations at the ENA Symposium, taking place November 18–20, 2026, in Barcelona, Spain. An oral plenary presentation will feature updated ERAS-0015 monotherapy data from the ongoing AURORAS-1 Phase 1 trial, including additional patients and longer follow-up. A poster presentation will feature nonclinical data for the combination of ERAS-0015 and ERAS-4001 targeting active and inactive KRAS, including synergy in KRAS G12X-driven models.

Corporate Highlights

•
Strengthened R&D Leadership: In August 2026, Erasca appointed Charles Fuchs, M.D., M.P.H., as president of research and development, and David Chonzi, M.D., as senior vice president of global pharmacovigilance, both of whom joined Erasca’s leadership team.

•
Completed Upsized Financing: In July 2026, Erasca completed a successful upsized public offering, raising approximately $632.5 million in gross proceeds.

Key Upcoming Milestones

AURORAS-1 to -3: Trials for ERAS-0015 (potential best-in-class pan-RAS molecular glue)

•
Phase 1 monotherapy expansion data expected in the first half of 2027
•
Phase 1 combination dose escalation data, including panitumumab combination, expected in the first half of 2027
•
Potentially registration-enabling trial in second line or greater NSCLC expected to initiate in the first half of 2027
•
Phase 3 pivotal trial in first line PDAC expected to initiate in 2027
•
Phase 3 pivotal trial in RASm NSCLC expected to initiate in the second half of 2027 to the first half of 2028

BOREALIS-1: Phase 1 trial for ERAS-4001 (potential first-in-class pan-KRAS inhibitor)

•
Preliminary safety, tolerability, pharmacokinetics, and initial efficacy Phase 1 monotherapy data expected in the second half of 2026
•
Initiation of monotherapy expansion cohorts and combination dose escalation cohorts planned for 2027

Third Quarter 2026 Financial Results

Cash Position: Cash, cash equivalents, and marketable securities were $947.8 million as of September 30, 2026, compared to $341.8 million as of December 31, 2025. Erasca expects its current cash, cash equivalents, and marketable securities will be sufficient to fund the Key Upcoming Milestones set forth above in this press release.

Research and Development (R&D) Expenses: R&D expenses were $47.2 million for the quarter ended September 30, 2026, compared to $22.5 million for the quarter ended September 30, 2025. The increase was primarily driven by increases in expenses incurred in connection with clinical trials, preclinical studies, discovery activities, personnel costs, including stock-based compensation expense, outsourced services, and consulting fees.

General and Administrative (G&A) Expenses: G&A expenses were $12.3 million for the quarter ended September 30, 2026, compared to $10.1 million for the quarter ended September 30, 2025. The increase was primarily driven by personnel costs, including stock-based compensation expense.

Net Loss: Net loss was $51.3 million, or $(0.15) per basic and diluted share, for the quarter ended September 30, 2026, compared to $30.6 million, or $(0.11) per basic and diluted share, for the quarter ended September 30, 2025.

(Press release, Erasca, NOV 12, 2026, View Source [SID1234674673])